Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Change in Receivables (2021 - 2025)

Historic Change in Receivables for HCW Biologics (HCWB) over the last 5 years, with Q3 2025 value amounting to $9056.0.

  • HCW Biologics' Change in Receivables rose 38905.2% to $9056.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$621173.0, marking a year-over-year decrease of 96659.28%. This contributed to the annual value of -$953556.0 for FY2024, which is 18528.66% down from last year.
  • Latest data reveals that HCW Biologics reported Change in Receivables of $9056.0 as of Q3 2025, which was up 38905.2% from -$65882.0 recorded in Q2 2025.
  • HCW Biologics' 5-year Change in Receivables high stood at $825678.0 for Q4 2023, and its period low was -$1.2 million during Q2 2021.
  • For the 5-year period, HCW Biologics' Change in Receivables averaged around -$129964.9, with its median value being -$3133.0 (2024).
  • In the last 5 years, HCW Biologics' Change in Receivables soared by 122873.83% in 2023 and then tumbled by 28302.99% in 2024.
  • Over the past 5 years, HCW Biologics' Change in Receivables (Quarter) stood at $63000.0 in 2021, then dropped by 1.37% to $62140.0 in 2022, then soared by 1228.74% to $825678.0 in 2023, then tumbled by 108.43% to -$69639.0 in 2024, then surged by 113.0% to $9056.0 in 2025.
  • Its last three reported values are $9056.0 in Q3 2025, -$65882.0 for Q2 2025, and -$494708.0 during Q1 2025.